The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 12, 2016
Filed:
Aug. 05, 2013
Bridged ring compounds as hepatitis c virus (hcv) inhibitors and pharmaceutical applications thereof
Applicant:
Sunshine Lake Pharma Co., Ltd, Dongguan, Guangdong, CN;
Inventors:
Yingjun Zhang, Dongguan, CN;
Jiancun Zhang, Dongguan, CN;
Hongming Xie, Dongguan, CN;
Qingyun Ren, Dongguan, CN;
Yumei Tan, Dongguan, CN;
Huichao Luo, Dongguan, CN;
Assignee:
Sunshine Lake Pharma Co., Ltd., Dongguan, Guangdong, CN;
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4178 (2006.01); C07D 403/14 (2006.01); C07D 401/14 (2006.01); C07D 413/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 453/06 (2006.01); C07D 471/08 (2006.01); C07D 491/056 (2006.01); C07D 493/08 (2006.01); C07D 519/00 (2006.01); A61K 31/4184 (2006.01); A61K 31/427 (2006.01); A61K 31/439 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 491/113 (2006.01); C07D 405/14 (2006.01);
U.S. Cl.
CPC ...
C07D 403/14 (2013.01); A61K 31/4178 (2013.01); A61K 31/4184 (2013.01); A61K 31/427 (2013.01); A61K 31/439 (2013.01); A61K 31/4545 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 453/06 (2013.01); C07D 471/08 (2013.01); C07D 491/056 (2013.01); C07D 491/113 (2013.01); C07D 493/08 (2013.01); C07D 519/00 (2013.01);
Abstract
Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.